Hemophilia Archives

Interview 9 Jan 2017

After a Rough Year, uniQure CMO discusses a Comeback

Last year was a bad year for biotech as an industry, but it was particularly bad for uniQure. Here’s what its CMO has to say about the company’s recovery. After giving the world its first gene therapy, uniQure has hit a series of rough patches since it rose to stardom as one of biotech’s success stories. […]

January 9, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 20 Dec 2016

UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data

UniQure’s gene therapy for Hemophilia B is performing well in clinical trials, but the company faces many challenges with its current financial situation. Can it manage to make it to the market? UniQure is famous for launching Glybera, the first globally approved gene therapy, which has been a commercial failure. The company is now indefinitely missing […]

December 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

liver anatomy organs Sebastian Kaulitzki fi

News and Trends 21 Nov 2016

“We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease”

Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I sat down with the CEO to hear more about the link between the company’s seemingly diverse interests and future direction. Promethera is the new kid on Belgium’s biotech block in Louvain-la-Neuve, and it’s hatching plans to make a splash with an IPO next spring. […]

November 21, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Nov 2016

Roche hits a Speed Bump on the way to a Hemophilia Cure

The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but a safety setback might slow its progress. There is a ‘bloody’ battle in Europe that no one is talking about: who will claim the next Hemophilia blockbuster drug? Roche has established itself as a force to be reckoned with via […]

November 4, 2016 - 4 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Hemophilia

After a Rough Year, uniQure CMO discusses a Comeback

UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data

“We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease”

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Roche hits a Speed Bump on the way to a Hemophilia Cure

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!